Fig. 8: Determining the potential of circCNOT6L as a therapeutic target at the organoid level. | Experimental & Molecular Medicine

Fig. 8: Determining the potential of circCNOT6L as a therapeutic target at the organoid level.

From: CircCNOT6L modulates alternative splicing of SLC7A11 via splicing factor SRSF2 to confer ferroptosis resistance and promote metastasis in prostate cancer

Fig. 8

a The possibility of using circCNOT6L-si in combination with erastin to treat PCa was evaluated by analyzing the growth of circCNOT6L-si in comparison to organoids in the si-circCNOT6L+erastin group after dimethyl sulfoxide treatment. b The proposed model of the mechanism of circCNOT6L promoting PCa malignant progression.

Back to article page